The antibody is directed against L-CA, the rat equivalent of CD45 which has a molecular weight 180-240kDa, and is present on all rat leukocytes, but not erythroid cells or cells of other tissues.
| Institute |
|---|
| Medical Research Council; University of Oxford |
| Cat. #: | 156559 |
|---|---|
| Unit size: | 100 ug |
| Application: | FACS ; IHC |
| Target: | CD45 (Leukocyte Common Antigen) |
| Reactivity: | Rat |
| Host: | Mouse |
| Class: | Monoclonal |
| Product description: | The antibody is directed against L-CA, the rat equivalent of CD45 which has a molecular weight 180-240kDa, and is present on all rat leukocytes, but not erythroid cells or cells of other tissues. |
|---|---|
| Conjugation: | Unconjugated |
| Immunogen: | A 100kD thymocyte glycoprotein fraction enriched for the rat leukocyte common antigen (L-CA) |
| Myeloma used: | NS1 |
| Target background: | The antibody is directed against L-CA, the rat equivalent of CD45 which has a molecular weight 180-240kDa, and is present on all rat leukocytes, but not erythroid cells or cells of other tissues. |
|---|
| Format: | Liquid |
|---|---|
| Shipping conditions: | Dry ice |
| References: |
Woollett et al. 1985. Eur J Immunol. 15(2):168-73. PMID: 2578966. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151015 | Anti-CyclinA [E70.1] |
Key Info
Anti-CyclinA [E70.1]
|
View Tool | |||||||||||||||||||
| 151016 | Anti-CyclinA [E72.1] |
Key Info
Anti-CyclinA [E72.1]
|
View Tool | |||||||||||||||||||
| 151021 | Anti-CyclinB1 [V152] |
Key Info
Anti-CyclinB1 [V152]
|
View Tool | |||||||||||||||||||
| 151025 | Anti-Vascular endothelium [10] |
Key Info
Anti-Vascular endothelium [10]
|
View Tool | |||||||||||||||||||
| 151039 | Anti-Integrin aVb3 [23C6] |
Key Info
Anti-Integrin aVb3 [23C6]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.